The company
Mineralys Therapeutics, Inc.
MLYS · Nasdaq
MLYS stood above a rising 150-day average in 15 of the last 52 weekly readings, and has been out of that trend for the last 36 weeks. It is 21.5% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 36
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $17.5M
- Insider sales, 12 months
- $114.0M
- Officials’ trades on record
- 0
- Institutions holding
- 217 (+14)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 15 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Jon CongletonChief Executive Officer | sold | 75,000at $25.46 | 30 Sep 2026filed 2 Oct 2026 |
| Brian Taylor SlingsbyDirector | sold | 104,320at $28.81 | 22 Sep 2026filed 24 Sep 2026 |
| Eric WarrenChief Commercial Officer | sold | 7,438at $28.12 | 21 Sep 2026filed 22 Sep 2026 |
| Daphne KarydasDirector | sold | 3,000at $28.58 | 15 Sep 2026filed 17 Sep 2026 |
| Eric WarrenChief Commercial Officer | sold | 7,437at $25.98 | 21 Aug 2026filed 25 Aug 2026 |
| David Malcom RodmanChief Medical Officer | sold | 2,170at $27.09 | 10 Aug 2026filed 12 Aug 2026 |
| Eric WarrenChief Commercial Officer | sold | 7,438at $26.87 | 21 Jul 2026filed 23 Jul 2026 |
| David Malcom RodmanChief Medical Officer | sold | 416at $26.53 | 17 Jul 2026filed 20 Jul 2026 |
| David Malcom RodmanChief Medical Officer | sold | 6,349at $26.61 | 15 Jul 2026filed 15 Jul 2026 |
| David Malcom RodmanChief Medical Officer | sold | 14,058at $27.58 | 13 Jul 2026filed 15 Jul 2026 |
| Jon CongletonChief Executive Officer | sold | 10,700at $27.24 | 13 Jul 2026filed 15 Jul 2026 |
| David Malcom RodmanChief Medical Officer | sold | 2,171at $30.30 | 9 Jul 2026filed 10 Jul 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| Catalys Pacific, LLCunchanged · filed 5 Aug 2026 | 7,903,838$213.2M | 00.0% |
| RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 2026 | 7,692,750$207.6M | 00.0% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 5,887,038$158.8M | +1,405,456+31.4% |
| SAMSARA BIOCAPITAL, LLCunchanged · filed 14 Aug 2026 | 5,871,018$158.4M | 00.0% |
| FMR LLCreduced · filed 13 Aug 2026 | 4,511,689$121.7M | -349,415−7.2% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 4,141,636$111.7M | +1,205,696+41.1% |
| DEERFIELD MANAGEMENT COMPANY, L.P.new · filed 14 Aug 2026 | 3,958,000$106.8M | +3,958,000 |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 2,756,770$74.4M | +302,407+12.3% |
| Laurion Capital Management LPadded · filed 13 Aug 2026 | 2,506,152$67.6M | +274,112+12.3% |
| ORBIMED ADVISORS LLCadded · filed 14 Aug 2026 | 2,110,300$56.9M | +57,400+2.8% |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.